Akalin Enver, Dinavahi Rajani, Dikman Steven, de Boccardo Graciela, Friedlander Rex, Schroppel Bernd, Sehgal Vinita, Bromberg Jonathan S, Heeger Peter, Murphy Barbara
Renal Division, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
Clin J Am Soc Nephrol. 2007 Nov;2(6):1261-7. doi: 10.2215/CJN.02420607. Epub 2007 Oct 17.
Transplant glomerulopathy (TGP) has been proposed to be a component of chronic antibody-mediated rejection (AMR). We have studied 36 patients with TGP and 51 patients with chronic allograft nephropathy (CAN) but without TGP for C4d staining and donor-specific anti-HLA antibodies (DSA) to investigate the alloantibody-mediated mechanisms.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Allograft biopsies were stained with C4d staining and DSAs were studied by Luminex Flow Beads. Allograft biopsies were done at a mean of 5.3 +/- 5.0 and 5.6 +/- 4.6 yr after transplantation in patients with CAN and TGP, respectively.
The mean creatinine level at the time of the biopsy was 2.7 +/- 1.2 mg/dl in each group. Proteinuria of >1.0 g/d was more common in patients with TGP (61 versus 25%; P = 0.002). Whereas three patients with TGP had a history of acute AMR, none of the patients with CAN had. Mean chronicity score of the biopsies were 1.7 +/- 0.7 in patients with CAN and 1.9 +/- 0.8 in patients with TGP. Biopsies from only two (4%) patients with CAN and four (11%) patients with TGP had diffuse C4d positivity. DSA were found in 36% of TGP and 33% of CAN patients.
These results suggest that a substantial number of patients with TGP did not have positive C4d staining or DSA, indicating that a non-alloantibody-mediated process may be involved in the development of TGP in some patients.
移植肾小球病(TGP)被认为是慢性抗体介导排斥反应(AMR)的一个组成部分。我们研究了36例TGP患者和51例慢性移植肾肾病(CAN)但无TGP的患者的C4d染色及供者特异性抗HLA抗体(DSA),以探讨同种抗体介导的机制。
设计、场所、参与者及测量方法:移植肾活检组织进行C4d染色,采用Luminex流式微球技术检测DSA。CAN和TGP患者移植肾活检分别在移植后平均5.3±5.0年和5.6±4.6年进行。
每组活检时的平均肌酐水平均为2.7±1.2mg/dl。TGP患者中蛋白尿>1.0g/d更为常见(61%对25%;P=0.002)。3例TGP患者有急性AMR病史,而CAN患者均无。CAN患者活检的平均慢性评分是1.7±0.7,TGP患者为1.9±0.8。仅2例(4%)CAN患者和4例(11%)TGP患者的活检组织有弥漫性C4d阳性。36%的TGP患者和33%的CAN患者检测到DSA。
这些结果表明,相当数量的TGP患者C4d染色或DSA未呈阳性,这表明在某些TGP患者的发病过程中可能涉及非同种抗体介导的过程。